Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
admission, AML, backbone, carboplatin, CFC, cisplatin, Daiichi, Deborah, declared, enable, enterprise, ERP, error, expenditure, fault, Fosun, futility, hardware, immunochemotherapy, immunologic, invoice, joint, magnitude, MDS, migration, monotherapy, myelodysplastic, myeloid, population, profile, properly, renal, rendered, resource, Sankyo, Shanghai, shortage, shutdown, solid, spanning, suffer, Telman, unfit, unrecognized, upgrade, venture, XinThera, Yikaida
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view